DOP2020000119A - Conjugados anticuerpo anti-cd40-fármaco - Google Patents
Conjugados anticuerpo anti-cd40-fármacoInfo
- Publication number
- DOP2020000119A DOP2020000119A DO2020000119A DO2020000119A DOP2020000119A DO P2020000119 A DOP2020000119 A DO P2020000119A DO 2020000119 A DO2020000119 A DO 2020000119A DO 2020000119 A DO2020000119 A DO 2020000119A DO P2020000119 A DOP2020000119 A DO P2020000119A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- antibody conjugates
- drug antibody
- antibody
- formula
- drug conjugates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762593807P | 2017-12-01 | 2017-12-01 | |
| US201762595045P | 2017-12-05 | 2017-12-05 | |
| PCT/IB2018/059480 WO2019106608A1 (en) | 2017-12-01 | 2018-11-29 | Anti-cd40 antibody drug conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2020000119A true DOP2020000119A (es) | 2020-08-31 |
Family
ID=66663861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2020000119A DOP2020000119A (es) | 2017-12-01 | 2020-06-15 | Conjugados anticuerpo anti-cd40-fármaco |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20220265842A1 (https=) |
| EP (1) | EP3716982A4 (https=) |
| JP (1) | JP2021504430A (https=) |
| KR (1) | KR20200095493A (https=) |
| CN (1) | CN111465399A (https=) |
| AU (1) | AU2018374633A1 (https=) |
| BR (1) | BR112020010691A2 (https=) |
| CA (1) | CA3081559A1 (https=) |
| CL (1) | CL2020001442A1 (https=) |
| CR (1) | CR20200285A (https=) |
| DO (1) | DOP2020000119A (https=) |
| EC (1) | ECSP20034868A (https=) |
| IL (1) | IL274650A (https=) |
| MX (1) | MX2020005465A (https=) |
| PE (1) | PE20201464A1 (https=) |
| PH (1) | PH12020550551A1 (https=) |
| RU (1) | RU2020117156A (https=) |
| SG (1) | SG11202004865SA (https=) |
| WO (1) | WO2019106608A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113271964A (zh) | 2019-01-11 | 2021-08-17 | 诺华股份有限公司 | 化脓性汗腺炎治疗中使用的抗cd40抗体 |
| AU2022205664A1 (en) * | 2021-01-07 | 2023-08-17 | Immunext, Inc. | NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCs CONTAINING AND USE THEREOF |
| CA3207416A1 (en) * | 2021-02-04 | 2022-08-11 | Lingjian ZHU | Drug conjugate of glucocorticoid receptor agonist, and application thereof in medicine |
| AR125084A1 (es) | 2021-03-23 | 2023-06-07 | Lilly Co Eli | Agonistas del receptor de glucocorticoides novedosos |
| AR125079A1 (es) | 2021-03-23 | 2023-06-07 | Lilly Co Eli | Agonistas de receptores de glucocorticoides sustituidos con carboxi |
| CN117043172A (zh) * | 2021-03-23 | 2023-11-10 | 伊莱利利公司 | 糖皮质激素受体激动剂 |
| TWI899455B (zh) | 2021-03-23 | 2025-10-01 | 美商美國禮來大藥廠 | 糖皮質素受體激動劑 |
| CN117580849A (zh) * | 2021-06-24 | 2024-02-20 | 江苏先声药业有限公司 | 甾体类化合物、其药物组合物及其应用 |
| CN120463762A (zh) * | 2021-08-26 | 2025-08-12 | 映恩生物科技(上海)有限公司 | 一种甾体化合物及其缀合物 |
| US20250179114A1 (en) * | 2021-09-14 | 2025-06-05 | Duality Biologics (Suzhou) Co., Ltd. | Anti-Inflammatory Compound and Use Thereof |
| KR102835682B1 (ko) * | 2022-06-16 | 2025-07-22 | 애브비 바이오테라퓨틱스 인크. | 항-cd19 항체-약물 접합체 |
| CN120239705A (zh) | 2022-07-21 | 2025-07-01 | 萤火虫生物股份有限公司 | 糖皮质激素受体激动剂和其缀合物 |
| JP2025532110A (ja) * | 2022-09-22 | 2025-09-29 | イーライ リリー アンド カンパニー | グルココルチコイド受容体アゴニスト |
| TW202432588A (zh) * | 2022-12-28 | 2024-08-16 | 大陸商蘇州盛迪亞生物醫藥有限公司 | 一種cd40結合分子的組成物及醫藥用途 |
| TW202430226A (zh) * | 2022-12-28 | 2024-08-01 | 大陸商上海盛迪醫藥有限公司 | 抗cd40抗體藥物偶聯物、其製備方法及其醫藥用途 |
| WO2026035986A1 (en) | 2024-08-07 | 2026-02-12 | Bighat Biosciences, Inc. | Humanized anti-cdh17 antibodies and use of the same |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4686650B2 (ja) * | 2007-11-30 | 2011-05-25 | ファイザー・リミテッド | 新規なグルココルチコイド受容体アゴニスト |
| WO2009085879A2 (en) * | 2007-12-21 | 2009-07-09 | Schering Corporation | C20-c21 substituted glucocorticoid receptor agonists |
| ES2709654T3 (es) * | 2011-04-29 | 2019-04-17 | Apexigen Inc | Anticuerpos anti-CD40 y métodos de uso |
| GB201309807D0 (en) * | 2013-05-31 | 2013-07-17 | Pharma Mar Sau | Antibody drug conjugates |
| US10550190B2 (en) * | 2014-04-04 | 2020-02-04 | Merck Sharp & Dohme Corp. | Phosphate based linkers for intracellular delivery of drug conjugates |
| CN107810198B (zh) * | 2015-05-29 | 2021-09-03 | 艾伯维公司 | 抗cd40抗体及其用途 |
| US20180126000A1 (en) * | 2016-06-02 | 2018-05-10 | Abbvie Inc. | Glucocorticoid receptor agonist and immunoconjugates thereof |
-
2018
- 2018-11-29 WO PCT/IB2018/059480 patent/WO2019106608A1/en not_active Ceased
- 2018-11-29 RU RU2020117156A patent/RU2020117156A/ru unknown
- 2018-11-29 SG SG11202004865SA patent/SG11202004865SA/en unknown
- 2018-11-29 CN CN201880077793.3A patent/CN111465399A/zh active Pending
- 2018-11-29 BR BR112020010691-7A patent/BR112020010691A2/pt not_active Application Discontinuation
- 2018-11-29 CR CR20200285A patent/CR20200285A/es unknown
- 2018-11-29 EP EP18883152.3A patent/EP3716982A4/en not_active Withdrawn
- 2018-11-29 MX MX2020005465A patent/MX2020005465A/es unknown
- 2018-11-29 US US16/768,616 patent/US20220265842A1/en not_active Abandoned
- 2018-11-29 AU AU2018374633A patent/AU2018374633A1/en not_active Abandoned
- 2018-11-29 CA CA3081559A patent/CA3081559A1/en active Pending
- 2018-11-29 KR KR1020207017805A patent/KR20200095493A/ko active Pending
- 2018-11-29 JP JP2020529611A patent/JP2021504430A/ja not_active Ceased
- 2018-11-29 PE PE2020000592A patent/PE20201464A1/es unknown
-
2020
- 2020-05-04 PH PH12020550551A patent/PH12020550551A1/en unknown
- 2020-05-13 IL IL274650A patent/IL274650A/en unknown
- 2020-05-29 CL CL2020001442A patent/CL2020001442A1/es unknown
- 2020-06-15 DO DO2020000119A patent/DOP2020000119A/es unknown
- 2020-06-29 EC ECSENADI202034868A patent/ECSP20034868A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202004865SA (en) | 2020-06-29 |
| JP2021504430A (ja) | 2021-02-15 |
| ECSP20034868A (es) | 2020-08-31 |
| WO2019106608A1 (en) | 2019-06-06 |
| IL274650A (en) | 2020-06-30 |
| US20220265842A1 (en) | 2022-08-25 |
| MX2020005465A (es) | 2020-09-07 |
| PE20201464A1 (es) | 2020-12-17 |
| KR20200095493A (ko) | 2020-08-10 |
| PH12020550551A1 (en) | 2021-03-22 |
| CA3081559A1 (en) | 2019-06-06 |
| AU2018374633A1 (en) | 2020-05-21 |
| CR20200285A (es) | 2020-09-04 |
| RU2020117156A (ru) | 2022-01-04 |
| EP3716982A4 (en) | 2021-08-11 |
| CL2020001442A1 (es) | 2020-09-11 |
| BR112020010691A2 (pt) | 2020-11-10 |
| CN111465399A (zh) | 2020-07-28 |
| EP3716982A1 (en) | 2020-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2020000119A (es) | Conjugados anticuerpo anti-cd40-fármaco | |
| PY1917867A (es) | Picolinamidas como fungicidas | |
| CO2018010458A2 (es) | Composiciones y anticuerpos anti-tim-3 | |
| MX2024004531A (es) | Compuestos de piridazinona y usos de los mismos. | |
| MX375570B (es) | Conjugados de pirrolobenzodiazepina | |
| EA201791550A1 (ru) | Димеры бензодиазепинов, их конъюгаты и способы их получения и применения | |
| MX2019004690A (es) | Constructos de anticuerpos. | |
| MX2017007585A (es) | Anticuerpos anti-c10orf54 y usos de los mismos. | |
| MX373280B (es) | Anticuerpos anti-egfrviii y usos de los mismos. | |
| MX382791B (es) | Conjugados novedosos de glicano y uso de los mismos | |
| AR057237A1 (es) | Metodos y composiciones para actuar sobre la poliubiquitina | |
| BR112021011124A2 (pt) | Anelossomos e métodos de uso | |
| DOP2017000202A (es) | Desacetoxitubulisina h y análogos de esta | |
| CR20190268A (es) | Nuevos deribados de isoxazolil éter como pam de gaba a alfa5 | |
| BR112023024837A2 (pt) | Anticorpos anti-ccr8 | |
| CO2019011980A2 (es) | Formas cristalinas de (s)-afoxolaner | |
| CO2019013718A2 (es) | Anticuerpos anti-trkb | |
| PY18111999A (es) | Hidroxiisoxazolinas y derivados de estos | |
| CR20160070A (es) | Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos | |
| MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
| PY2027945A (es) | Tienilhidroxiisoxazolinas y derivados de las mismas | |
| MX2022000457A (es) | Composiciones microbianas. | |
| CO2021014351A2 (es) | Derivados de quinolina y su uso para el tratamiento del cáncer | |
| PY2027940A (es) | Hidroxiisoxazolinas y derivados de las mismas | |
| PY2027937A (es) | Hidroxiisoxazolinas y derivados de las mismas |